Clinical review: Statins and trauma - a systematic review

Critical Care

Volumn 17, Issue 3, 2013, Pages

  Jansen, Jan O ^a   Lord, Janet M ^b   Thickett, David R ^b   Midwinter, Mark J ^b   McAuley, Daniel F ^c   Gao, Fang ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BIBLIOGRAPHIC DATABASE; BRAIN INJURY; BURN; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COGNITION; COHORT ANALYSIS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; EMBASE; FRACTURE; FRACTURE HEALING; HAZARD RATIO; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INFECTION; INJURY; INJURY SEVERITY; MEDLINE; MORTALITY; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; DRUG ADMINISTRATION; PROCEDURES; WOUNDS AND INJURIES;

DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOUNDS AND INJURIES;

EID: 84878793733     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12499     Document Type: Review

References (59)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442. 10.1371/journal.pmed.0030442, 1664601, 17132052.
2. Stahel PF, Smith WR, Moore EE. Role of biological modifiers regulating the immune response after trauma. Injury 2007, 38:1409-1422. 10.1016/j.injury.2007.09.023, 18048034.
3. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: A bimodal phenomenon. J Trauma 1996, 40:501-510. discussion 510-512, 10.1097/00005373-199604000-00001, 8614027.
4. Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. Injury 2010, 41:21-26. 10.1016/j.injury.2009.07.010, 19729158.
5. Osborn TM, Tracy JK, Dunne JR, Pasquale M, Napolitano LM. Epidemiology of sepsis in patients with traumatic injury. Crit Care Med 2004, 32:2234.
6. Nast-Kolb D, Aufmkolk M, Rucholtz S, Obertacke U, Waydhas C. Multiple organ failure still a major cause of morbidity but not mortality in blunt multiple trauma. J Trauma 2001, 51:835. 10.1097/00005373-200111000-00003, 11706328.
7. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26(Suppl 1):S64-74.
8. Angus DC, Wax RS. Epidemiology of sepsis: An update. Crit Care Med 2001, 29(7 Suppl):S109-116.
9. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, Betten B, Bartels J, Constantine G, Fink MP, Billiar TR, Vodovotz Y. The acute inflammatory response in diverse shock states. Shock 2005, 24:74-84. 10.1097/01.shk.0000168526.97716.f3, 15988324.
10. Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury 2007, 38:1336-1345. 10.1016/j.injury.2007.10.003, 18048040.
11. Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Release of anti-inflammatory mediators after major torso trauma correlates with the development of postinjury multiple organ failure. Am J Surg 1999, 178:564-569. 10.1016/S0002-9610(99)00240-8, 10670873.
12. Jastrow KM, Gonzalez EA, McGuire MF, Suliburk JW, Kozar RA, Iyengar S, Motschall DA, McKinley BA, Moore FA, Mercer DW. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg 2009, 209:320-331. 10.1016/j.jamcollsurg.2009.05.002, 19717036.
13. Hranjec T, Swenson BR, Dossett LA, Metzger R, Flohr TR, Popovsky KA, Bonatti HJ, May AK, Sawyer RG. Diagnosis-dependent relationships between cytokine levels and survival in patients admitted for surgical critical care. J Am Coll Surg 2010, 210:833-844. 845-846, 10.1016/j.jamcollsurg.2009.12.042, 2861048, 20421061.
14. Chao Y, Chen JS, Hunt VM, Kuron GW, Karkas JD, Liou R, Alberts AW. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur J Clin Pharmacol 1991, 40(Suppl 1):S11-14.
15. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mrna for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986, 83:8370-8374. 10.1073/pnas.83.21.8370, 386930, 3464957.
16. Gao F, Linhartova L, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth 2008, 100:288-298. 10.1093/bja/aem406, 18276651.
17. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B, Alberta Kidney Disease Network Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. CMAJ 2011, 183:E1189-1202. 10.1503/cmaj.101280, 3216447, 21989464, Alberta Kidney Disease Network.
18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008, 359:2195-2207. 10.1056/NEJMoa0807646, 18997196, JUPITER Study Group.
19. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr Med Chem 2007, 14:243-248. 10.2174/092986707779313381, 17266583.
20. Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010, 16:3808-3814. 10.2174/138161210794455120, 21128896.
21. Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefer I, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoglu L. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) working group on atherosclerosis and vascular biology. Thromb Haemost 2011, 106:1-19. 10.1160/TH10-12-0784, 21670845.
22. Guasti L, Marino F, Cosentino M, Cimpanelli M, Maio RC, Klersy C, Crespi C, Restelli D, Simoni C, Franzetti I, Gaudio G, Marnini P, Grandi AM, Lecchini S, Venco A. Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: A longitudinal study. J Hypertens 2006, 24:2423-2430. 10.1097/01.hjh.0000251903.62804.77, 17082725.
23. Fischetti F, Carretta R, Borotto G, Durigutto P, Bulla R, Meroni PL, Tedesco F. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004, 135:186-193. 10.1111/j.1365-2249.2003.02358.x, 1808935, 14738444.
24. Hokama JY, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG, McDonagh PF. Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Complications 2000, 14:96-107. 10.1016/S1056-8727(00)00068-4, 10959072.
25. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002, 23:482-487. 10.1016/S0165-6147(02)02077-1, 12368073.
26. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS, McAuley DF. A randomized clinical trial of hydroxymethylglutarylcoenzyme a reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med 2011, 183:620-626. 10.1164/rccm.201003-0423OC, 20870757.
27. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107-1114. 10.1164/rccm.200810-1584OC, 2695496, 19324974.
28. Efron DT, Sorock G, Haut ER, Chang D, Schneider E, Mackenzie E, Cornwell EE, Jurkovich GJ. Preinjury statin use is associated with improved in-hospital survival in elderly trauma patients. J Trauma 2008, 64:66-73. discussion 73-74, 10.1097/TA.0b013e31815b842a, 18188101.
29. Neal MD, Cushieri J, Rosengart MR, Alarcon LH, Moore EE, Maier RV, Minei JP, Billiar TR, Peitzman AB, Sperry JL, Inflammation and Host Response to Injury Investigators Preinjury statin use is associated with a higher risk of multiple organ failure after injury: A propensity score adjusted analysis. J Trauma 2009, 67:476-82. discussion 482-484, 10.1097/TA.0b013e3181ad66bb, 19741387, Inflammation and Host Response to Injury Investigators.
30. Schneider EB, Efron DT, MacKenzie EJ, Rivara FP, Nathens AB, Jurkovich GJ. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma 2011, 71:815-819. 10.1097/TA.0b013e3182319de5, 21986733.
31. Tapia-Perez J, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma 2008, 25:1011-1017. 10.1089/neu.2008.0554, 18690806.
32. Fogerty MD, Efron D, Morandi A, Guy JS, Abumrad NN, Barbul A. Effect of preinjury statin use on mortality and septic shock in elderly burn patients. J Trauma 2010, 69:99-103. 10.1097/TA.0b013e3181df61b1, 20622585.
33. Akcay MN, Avkay G, Kiziltunc A, Ozturk G, Aydinli B. The effect of short-term treatment with atorvastatin on e-selectin levels in severely burned patients. Int J Clin Pharm Res 2005, 25:65-69.
34. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutarylcoenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185-2188. 10.1016/S0140-6736(00)02400-4, 10881890.
35. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205-3210. 10.1001/jama.283.24.3205, 10866867.
36. Nichols R, Hopman WM, Morton AR, Harman GJ, Holden RM. Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients. Hemodial Int 2008, 12:275-279. 10.1111/j.1542-4758.2008.00265.x, 18394063.
37. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch Intern Med 2002, 162:537. 10.1001/archinte.162.5.537, 11871921.
38. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sørensen HT, Mosekilde L. Hip fracture risk in statin users--a population-based danish case-control study. Osteoporos Int 2004, 15:452-458.
39. Rejnmark L, Vestergaard P, Mosekilde L. Statin but not non-statin lipid-lowering drugs decrease fracture risk: A nation-wide case-control study. Calcified Tissue Int 2006, 79:27-36.
40. Schoofs MW, Sturkenboom MC, van der Klift M, Hofman A, Pols HA, Stricker BH. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 2004, 19:1525-1530. 10.1359/JBMR.040607, 15312254.
41. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk: Study of a US veterans population. Arch Intern Med 2005, 165:2007. 10.1001/archinte.165.17.2007, 16186471.
42. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000, 283:3211-3216. 10.1001/jama.283.24.3211, 10866868.
43. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N. Effect of pravastatin on frequency of fracture in the LIPID study: Secondly analysis of a randomised controlled trial. Lancet 2001, 357:509-512. 10.1016/S0140-6736(00)04042-3, 11229669.
44. Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial. Bone 2005, 37:190-191. 10.1016/j.bone.2005.04.012, 15936996.
45. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007, 92:4671-4677. 10.1210/jc.2006-1909, 17726081.
46. Patil S, Holt G, Raby N, McLellan AR, Smith K, O'Kane S, Beastall G, Crossan JF. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res 2009, 27:281-285. 10.1002/jor.20572, 18853428.
47. Pfeifer R, Tarkin IS, Rocos B, Pape HC. Patterns of mortality and causes of death in polytrauma patients--has anything changed?. Injury 2009, 40:907-911. 10.1016/j.injury.2009.05.006, 19540488.
48. ClinicalTrials.gov Statins for acutely injured lungs from sepsis (SAILS). ClinicalTrials.gov., http://clinicaltrials.gov/ct2/show/NCT00979121
49. McAuley DF, Laffey JG, O'Kane CM, Cross M, Perkins GD, Murphy L, McNally C, Crealey G, Stevenson M, HARP-2 investigators on behalf of the Irish Critical Care Trials Grou Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: Study protocol for a randomized controlled trial. Trials 2012, 13:170. 10.1186/1745-6215-13-170, 3543316, 22985805, HARP-2 investigators on behalf of the Irish Critical Care Trials Grou.
50. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452. 10.1161/01.CIR.0000012530.68333.C8, 11914253, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators.
51. Le Manach Y, Godet G, Coriat P, Martinon C, Bertrand M, Fléron MH, Riou B. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007, 104:1326-1333. 10.1213/01.ane.0000263029.72643.10, 17513620.
52. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R, Feringa HH, Dunkelgrun M, van Domburg RT, Bax JJ, Poldermans D. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007, 100:316-320. 10.1016/j.amjcard.2007.02.093, 17631090.
53. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, National H, Lung and Blood Institute ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024-1028. 10.1161/01.CIR.0000032466.44170.44, 12186811, Lung and Blood Institute.
54. Bickel C, Rupprecht HJ, Blankenberg S, Espinola-Klein C, Rippin G, Hafner G, Lotz J, Prellwitz W, Meyer J, AtheroGene Group Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002, 82:25-31. 10.1016/S0167-5273(01)00576-9, 11786154, AtheroGene Group.
55. Krysiak R, Okopień B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003, 63:1821-1854. 10.2165/00003495-200363170-00005, 12921488.
56. Bourcier T, Libby P. HMG coa reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:556-562. 10.1161/01.ATV.20.2.556, 10669656.
57. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999, 95:229-234. 10.1016/S0049-3848(99)00037-7, 10515287.
58. Mayer J, Eller T, Brauer P, Solleder EM, Schäfer RM, Keller F, Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992, 64:196-201. 10.1007/BF01696223, 1581407.
59. Notarbartolo A, Davì G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:247-251. 10.1161/01.ATV.15.2.247, 7749833.